Institutional members access full text with Ovid®

Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder

Montgomery, Stuart A.a; Locklear, Julie C.b; Svedsäter, Henrikc; Eriksson, Hansc

International Clinical Psychopharmacology: September 2014 - Volume 29 - Issue 5 - p 252–262
doi: 10.1097/YIC.0000000000000026
Original Articles

This study is a pooled, post-hoc analysis evaluating once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Three previously reported positive, 8-week, randomized, double-blind, placebo-controlled studies evaluated quetiapine XR therapy (50, 150, 300 mg/day) in patients with GAD [Hamilton Anxiety Rating Scale (HAM-A) total score≥20]. Patients were stratified by baseline severity: HAM-A total score ≥22, ≥24, <26, ≥26, ≥28. We report HAM-A total score change, response (≥50% reduction in HAM-A total score), and remission (HAM-A total score≤7 and ≤9). Quetiapine XR significantly improved HAM-A total scores compared with placebo at Weeks 1 and 8 in the HAM-A ≥22, ≥24, and ≥26 cohorts (all doses), at Week 1 (all doses) and Week 8 (quetiapine XR 150 mg/day) in the <26 cohort, and at Week 1 (all doses) and Week 8 (quetiapine XR 50 and 150 mg/day) in the HAM-A≥28 group (P<0.05). Week 8 effect sizes for 50, 150, and 300 mg/day were as follows: 0.29, 0.47, 0.17 (HAM-A≥22); 0.35, 0.55, 0.22 (HAM-A≥24); 0.18, 0.32, 0.10 (HAM-A<26); 0.41, 0.59, 0.24 (HAM-A≥26); 0.60, 0.64, 0.22 (HAM-A≥28), respectively. Acute quetiapine XR monotherapy significantly improves anxiety compared with placebo in patients with moderate or severe GAD, with symptom improvements seen as early as Week 1.

aImperial College School of Medicine, University of London, London, UK

bAstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA

cAstraZeneca R&D, Södertälje, Sweden

Clinical trials registry numbers: clinicaltrials.gov NCT00329264; NCT00329446; NCT00322595.

Correspondence to Stuart A. Montgomery, PO Box 8751, London W13 8WH, UK Fax: +44 20 8566 7986; e-mail: stuart@samontgomery.co.uk

Received September 19, 2013

Accepted December 2, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins